DOP2016000284A - Proteínas agonistas de los receptores de trail de cadena simple. - Google Patents

Proteínas agonistas de los receptores de trail de cadena simple.

Info

Publication number
DOP2016000284A
DOP2016000284A DO2016000284A DO2016000284A DOP2016000284A DO P2016000284 A DOP2016000284 A DO P2016000284A DO 2016000284 A DO2016000284 A DO 2016000284A DO 2016000284 A DO2016000284 A DO 2016000284A DO P2016000284 A DOP2016000284 A DO P2016000284A
Authority
DO
Dominican Republic
Prior art keywords
trail
agonist proteins
receivers
single chain
proteins
Prior art date
Application number
DO2016000284A
Other languages
English (en)
Inventor
Oliver Hill
Christian Gieffers
Meinolf Thiemann
Fritz G Buchanan
Darren C Phillips
Susan E Lappe
Original Assignee
Abbvie Inc
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc
Publication of DOP2016000284A publication Critical patent/DOP2016000284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)

Abstract

Proteínas específicas que son agonistas de los receptores de TRAIL. Ácidos nucleicos que las codifican. Métodos para tratar una enfermedad o un trastorno asociado a los TRAIL en un sujeto. Las proteínas agonistas de los receptores de TRAIL que se proveen en la presente comprenden tres dominios de TRAIL solubles y un fragmento Fc. Las proteínas agonistas de los receptores de TRAIL no forman agregados de manera sustancial y son apropiadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación. fig. 17B
DO2016000284A 2014-04-23 2016-10-19 Proteínas agonistas de los receptores de trail de cadena simple. DOP2016000284A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
DOP2016000284A true DOP2016000284A (es) 2017-02-15

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000284A DOP2016000284A (es) 2014-04-23 2016-10-19 Proteínas agonistas de los receptores de trail de cadena simple.

Country Status (37)

Country Link
US (4) US9908927B2 (es)
EP (2) EP3134430B1 (es)
JP (2) JP6523331B2 (es)
KR (2) KR20190135546A (es)
CN (2) CN106459221B (es)
AR (1) AR100168A1 (es)
AU (3) AU2015249649B2 (es)
BR (1) BR112016024515B1 (es)
CA (2) CA3184067A1 (es)
CL (1) CL2016002683A1 (es)
CR (1) CR20160516A (es)
CY (1) CY1120281T1 (es)
DK (1) DK3134430T3 (es)
DO (1) DOP2016000284A (es)
EC (1) ECSP16089579A (es)
ES (1) ES2672368T3 (es)
HR (1) HRP20180950T1 (es)
HU (1) HUE038914T2 (es)
IL (2) IL248244B (es)
LT (1) LT3134430T (es)
MA (2) MA45069A (es)
MX (2) MX2016013858A (es)
MY (1) MY181986A (es)
NO (1) NO2776305T3 (es)
PE (1) PE20170299A1 (es)
PH (1) PH12016502079A1 (es)
PL (1) PL3134430T3 (es)
PT (1) PT3134430T (es)
RS (1) RS57153B1 (es)
RU (1) RU2699285C2 (es)
SG (3) SG10201806465TA (es)
SI (1) SI3134430T1 (es)
TR (1) TR201806912T4 (es)
TW (2) TWI683825B (es)
UA (1) UA118286C2 (es)
UY (1) UY36095A (es)
WO (1) WO2015164588A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014140A (es) 2015-05-04 2018-03-15 Apogenix Ag Proteinas agonistas receptoras cd40 de cadena simple.
AU2016342420B2 (en) 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
JP6959229B2 (ja) * 2015-10-23 2021-11-02 アポジェニックス アーゲー 一本鎖ｇｉｔｒ受容体アゴニストタンパク質
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
US10821160B2 (en) 2016-03-01 2020-11-03 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
JP2019518713A (ja) * 2016-03-16 2019-07-04 メリマック ファーマシューティカルズ インコーポレーティッド 癌療法のための改変ｔｒａｉｌ
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
WO2019032952A1 (en) * 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
US20230212260A1 (en) 2020-05-15 2023-07-06 Apogenix Ag Multi-specific immune modulators
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025984A1 (es) 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
CA2716959A1 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003091447A2 (en) 2002-04-26 2003-11-06 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
ATE445644T1 (de) 2005-04-15 2009-10-15 Rappaport Family Inst For Res Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
EP3321277B1 (en) 2007-07-10 2019-09-18 Apogenix AG Tnf superfamily collectin fusion proteins
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
PL2604693T3 (pl) * 2008-07-21 2016-09-30 Jednołańcuchowe cząsteczki TNFSF
AU2009293545A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Ｔｒａｉｌ−ｒ１及びｔｒａｉｌ−ｒ２に結合するポリペプチド
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
US20130011401A1 (en) 2009-12-22 2013-01-10 Novartis Ag Soluble proteins for use as therapeutics
US20130079280A1 (en) 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds
US9717803B2 (en) * 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
US9434783B2 (en) 2012-07-18 2016-09-06 Apogenix Ag Shortened CD95-Fc variant fusion proteins, nucleic acids and host cells thereof

Also Published As

Publication number Publication date
KR20190135546A (ko) 2019-12-06
EP3366699A1 (en) 2018-08-29
JP6523331B2 (ja) 2019-05-29
ES2672368T3 (es) 2018-06-14
US20150337027A1 (en) 2015-11-26
MX2019013587A (es) 2020-01-13
UY36095A (es) 2015-10-30
TWI747178B (zh) 2021-11-21
US20240174731A1 (en) 2024-05-30
EP3134430B1 (en) 2018-03-21
PH12016502079B1 (en) 2016-12-19
HUE038914T2 (hu) 2018-12-28
EP3134430A1 (en) 2017-03-01
CA2946402A1 (en) 2015-10-29
JP6714751B2 (ja) 2020-06-24
DK3134430T3 (en) 2018-05-22
PT3134430T (pt) 2018-04-20
PE20170299A1 (es) 2017-05-06
SG10201806465TA (en) 2018-08-30
LT3134430T (lt) 2018-05-10
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
AU2015249649A1 (en) 2016-11-10
SI3134430T1 (en) 2018-05-31
TW202024123A (zh) 2020-07-01
TW201620928A (zh) 2016-06-16
CY1120281T1 (el) 2019-07-10
US20180222962A1 (en) 2018-08-09
CA2946402C (en) 2023-02-28
KR20170012257A (ko) 2017-02-02
NO2776305T3 (es) 2018-01-27
NZ725476A (en) 2023-09-29
AU2015249649B2 (en) 2018-10-04
KR102079919B1 (ko) 2020-02-24
CR20160516A (es) 2017-05-10
AU2018271369A1 (en) 2018-12-20
MY181986A (en) 2021-01-18
IL272612A (en) 2020-03-31
UA118286C2 (uk) 2018-12-26
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
AR100168A1 (es) 2016-09-14
SG10202111785VA (en) 2021-12-30
MA39770A (fr) 2015-10-29
RU2699285C2 (ru) 2019-09-04
PL3134430T3 (pl) 2018-08-31
JP2017513503A (ja) 2017-06-01
CN106459221B (zh) 2020-09-01
JP2019162114A (ja) 2019-09-26
RU2016145608A (ru) 2018-05-28
RU2016145608A3 (es) 2018-12-26
TR201806912T4 (tr) 2018-06-21
TWI683825B (zh) 2020-02-01
RS57153B1 (sr) 2018-07-31
BR112016024515B1 (pt) 2020-03-31
MX2016013858A (es) 2017-08-02
ECSP16089579A (es) 2018-05-31
CL2016002683A1 (es) 2017-07-07
US9908927B2 (en) 2018-03-06
US20210040178A1 (en) 2021-02-11
IL248244B (en) 2020-03-31
MA45069A (fr) 2019-04-03
WO2015164588A1 (en) 2015-10-29
SG11201608767XA (en) 2016-11-29
PH12016502079A1 (en) 2016-12-19
IL248244A0 (en) 2016-11-30
BR112016024515A2 (pt) 2017-10-10
AU2020202247A1 (en) 2020-04-23
HRP20180950T1 (hr) 2018-08-10

Similar Documents

Publication Publication Date Title
DOP2016000284A (es) Proteínas agonistas de los receptores de trail de cadena simple.
CL2018003406A1 (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo.
CY1119098T1 (el) Αγωνιστες fgfr1 και μεθοδοι χρησης
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
PE20181349A1 (es) Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
DK3134123T3 (da) Il-2r-beta-selektive agonister i kombination med et anti-ctla-4-antistof eller et anti-pd-1-antistof
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
ECSP17080639A (es) Moléculas de unión a lag-3 y métodos de uso de las mismas
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
PH12016500781A1 (en) Novel anti-claudin antibodies and methods of use
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CR20180348A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
BR112017023131A2 (pt) anticorpos anti- fcrn
DK3212123T3 (da) Apparat til vaginal penetrering af dyr med et visningssystem, især til lokalisering af livmoderhalsen
BR112016010822A2 (pt) anticorpos específicos para fcrn
UY36455A (es) Antagonistas del receptor ep3 de prostaglandinas
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
BR112019011461A2 (pt) terapia celular à base de nk melhorada
CL2015002365A1 (es) Métodos para uso de semen sexado para mejorar la gestión genética en cerdos
CL2016001357A1 (es) Agonistas de a1 de adenosina como medicamentos para trastornos renales
CL2016002710A1 (es) Anticuerpos monoclonales específicos para cry1ca y métodos de detección relacionados